What is Nurix Therapeutics Forward Dividend Yield %?
As of today (2024-05-15), the Forward Annual Dividend Yield of Nurix Therapeutics is 0.00%.
As of today (2024-05-15), the Trailing Annual Dividend Yield of Nurix Therapeutics is 0.00%.
NRIX's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.55 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Nurix Therapeutics's Forward Dividend Yield %
For the Biotechnology subindustry, Nurix Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nurix Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Nurix Therapeutics's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Nurix Therapeutics Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Nurix Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Nurix Therapeutics (Nurix Therapeutics) Business Description
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NRIX has been successfully added to your